"Take two of these and call me in the morning," will have to remain the saying for Johnson & Johnson's
Literally. The pill itself is the only thing that got rejected.
Prezista is still on the market, and Johnson & Johnson can still market it as a once-daily treatment for HIV. The company just can't sell an 800-mg version of the drug it developed. Patients who want to take Prezista as a once-daily drug will have to continue taking two 400-mg pills.
What's wrong with the 800-mg pill? Johnson & Johnson didn't say, but did point out that it doesn't think additional clinical trials will be required to satisfy the FDA. The potential culprit could be a manufacturing issue or a problem proving that the 800-mg pill releases the same amount of drug as two 400-mg pills. Either way, it's probably not that big a deal to rectify although investors should be a little worried that it happened in the first place. Johnson & Johnson should know how to satisfy the FDA's requirements to get a new dosage approved.
In theory, the rejection could keep Johnson & Johnson from selling the 800-mg pill for six months or more. Waiting for the approval isn't the end of the world, but it certainly would be nice to have the higher-dose pill approved. For many diseases, taking two pills is fairly common. But HIV patients usually don't take just one medication. Prezista is always taken with Abbott Labs'
That's a lot of pills compared to Atripla, which contains Truvada and Bristol-Myers Squibb's
First, though, the pharma has to convince the FDA that its one-pill dose is approvable, something that seems a little more elusive than it should be.
Dividends can help investors ride the waves of slow drug development times. Check out the Fool's free report "Secure Your Future With 9 Rock-Solid Dividend Stocks," where you'll find one drug developer and eight other promising companies. Just click here to get your free copy.